T 1732/18 of 27.10.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T173218.20211027
- Date of decision
- 27 October 2021
- Case number
- T 1732/18
- Petition for review of
- -
- Application number
- 06706291.9
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- TREATMENT OF THROMBOEMBOLIC DISORDERS WITH RIVAROXABAN
- Applicant name
- Bayer Intellectual Property GmbH
- Opponent name
- Breuer, Markus (opposition withdrawn)
Actavis Group PTC ehf
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Teva Pharmaceutical Industries Ltd.
STADA Arzneimittel AG
Generics [UK] Limited (trading as Mylan)
Abdi Ibrahim Ilaç Sanayi ve Ticaret Anonim Sirketi
Wittkopp, Alexander
Galenicum Health S.L.
ABG Intellectual Property Law, S.L.
Stolmár, Matthias
Hexal AG
Kraus & Weisert Patentanwälte PartGmbB
Zentiva k.s.
Krka, d.d., Novo mesto - Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(b)European Patent Convention Art 100(c)European Patent Convention Art 105European Patent Convention Art 113(1)European Patent Convention Art 123(2)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention R 79Rules of procedure of the Boards of Appeal 2020 Art 013(2)
- Keywords
- Amendments - added subject-matter (no)
Novelty - (yes)
Admittance of evidence filed in Appeal
Admittance of submissions filed at a late stage
Sufficiency of disclosure (yes)
Inventive step - (yes) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The oppositions are rejected.
3. The patent is maintained as granted.